StockData
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. (CLRB) shareholders

CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.14−0.02 (-1.72%)

Close on Nov 13, 2026Market cap $10.78MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
36.8%
3M of 9M shares
Institutional holders
29
14 new, 4 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
2 buys · 1 sales
Net bought $49.26K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Salamon Steven A J
Joint filing with Rosalind Advisors, Inc. (9.90%), Aharon Gil (9.90%) and 1 more
7,472,7459.90%13G (passive) amendmentDec 31, 2024
Nantahala Capital Management, LLC
Joint filing with Wilmot B. Harkey (5.73%), Daniel Mack (5.73%)
2,507,1255.73%13G (passive) amendmentDec 31, 2024
ADAR1 Partners, LP
Joint filing with ADAR1 Capital Management, LLC (6.21%), ADAR1 Capital Management GP, LLC (6.21%) and 1 more
1,824,0636.21%13G (passive)Jan 23, 2024
Rockledge Capital Corporation
Joint filing with Lincoln Park Capital Fund, LLC (9.68%), Lincoln Park Capital, LLC (9.68%) and 3 more
1,307,0499.68%13G (passive) amendmentDec 31, 2023
Empery Asset Management, LP
Joint filing with Ryan M. Lane (9.99%)
864,0909.99%13G (passive)Jun 30, 2026
Stonepine GP, LLC
Joint filing with Stonepine Capital Management, LLC (9.90%), Stonepine Capital, L.P. (9.90%) and 1 more
863,2779.90%13G (passive)May 4, 2026
Devesh Gandhi
Joint filing with SilverArc Capital Management, LLC (9.99%)
851,2859.99%13G (passive)Jun 30, 2026
Michelle Ross
Joint filing with StemPoint Capital LP (9.90%), StemPoint Capital Management GP LLC (9.90%)
845,7409.90%13G (passive)Jun 30, 2026
Bleichroeder Holdings LLC
Joint filing with Bleichroeder LP (9.99%), Andrew Gundlach (9.99%)
808,3009.99%13G (passive)Jun 30, 2026
Dmitry Balyasny
Joint filing with Balyasny Asset Management L.P. (9.99%), Bam Gp LLC (9.99%) and 2 more
798,3829.99%13G (passive)Jun 30, 2026
Janus Henderson Group PLC798,3829.99%13G (passive)May 29, 2026
Johnson David Edward
Joint filing with Caligan Partners LP (5.90%)
469,9985.90%13G (passive)Jun 30, 2026
Aharon Gil
Joint filing with Rosalind Advisors, Inc. (5.50%), Salamon Steven A J (5.50%)
247,7155.50%13G (passive) amendmentDec 31, 2025
Andrew Gundlach
Joint filing with Bleichroeder LP (6.08%), Bleichroeder Holdings LLC (6.08%)
200,0006.08%13G (passive)Sep 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of CLRBValueChange% of portfolio
Caligan Partners LP469,9984.97%$1.31MNew0.06%
Nantahala Capital Management, LLC439,9964.66%$1.22MNew0.02%
Stempoint Capital LP354,9383.76%$986.73KNew0.17%
Vanguard Capital Management LLC327,3673.46%$910.08K+245,4830.00%
Silverarc Capital Management, LLC321,7283.40%$894.40KNew0.09%
Bleichroeder LP288,6793.05%$802.53K+188,6790.14%
Jupiter Topco LLC274,1562.90%$759.41KNew0.00%
Balyasny Asset Management L.P.220,0002.33%$611.60KNew0.00%
Empery Asset Management, LP189,6052.01%$527.10KNew0.61%
Diadema Partners LP138,3411.46%$384.59KNew0.05%
Stonepine Capital Management, LLC104,5501.11%$290.65KNew0.16%
Persistent Asset Partners Ltd92,9830.98%$258.49KNew0.08%
Boothbay Fund Management, LLC85,0690.90%$236.49KNew0.00%
Geode Capital Management, LLC53,3510.56%$148.32K+5730.00%
Vanguard Fiduciary Trust Co46,2200.49%$128.49K+29,6470.00%
Sequoia Financial Advisors, LLC21,8500.23%$60.74K+3,0000.00%
Acadian Asset Management LLC16,5770.18%$46.00KNew0.00%
Northern Trust Corp14,8390.16%$41.25KNew0.00%
Riverview Capital Advisers, LLC10,3840.11%$50.05K–0.01%
BlackRock, Inc.4,7350.05%$13.16K−100.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026293M36.8%14 / 62 / 43M0M
Q1 2026190M3.3%4 / 23 / 40M0M
Q4 2025200M3.7%4 / 71 / 50M0M
Q3 2025210M3.1%6 / 73 / 40M0M
Q2 2025190M1.1%19 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

7 funds held CLRB in Q2 2026, 90% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of CLRBValue% of fundAs of
Vanguard Total Stock Market Index Fund184,1451.95%$511.92K0.00%Jun 30, 2026
Vanguard Extended Market Index Fund143,2221.52%$398.16K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund26,9770.29%$84.71K0.00%May 31, 2026
Fidelity Series Total Market Index Fund5,6410.06%$17.71K0.00%May 31, 2026
Fidelity Total Market Index Fund2,0640.02%$6.48K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund2000.00%$6280.00%May 31, 2026
Blackstone Alternative Multi-Strategy Fund10.00%$30.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
James V. CarusoPresident & CEO, Director20,3180.21%Jul 8, 2026
Jarrod LongcorChief Operating Officer20,4510.22%Jul 8, 2026
Chad J. KoleanCFO6,4180.07%Jul 8, 2026
John NeisDirector100.00%Jul 8, 2026
Asher Chanan-KhanDirector––Jul 8, 2026
Andrew GuDirector––Jul 8, 2026
Frederick W. DriscollDirector19,4170.21%Jul 8, 2026
Douglas J. SwirskyDirector25,0000.26%Jul 8, 2026
Stefan Loren–––Jul 10, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jarrod Longcor
Chief Operating Officer
May 7, 2026Buy+8,680$2.88$25.00K20,451
James V. Caruso
Chief Executive Officer, Director
May 7, 2026Buy+8,680$2.88$25.00K20,318
John Neis
Director
Dec 12, 2025Sale−198$3.70$73310
James V. Caruso
Chief Executive Officer, Director
Jul 2, 2025Buy+10,000$4.99$49.90K11,638
Jarrod Longcor
Chief Operating Officer
Jul 2, 2025Buy+10,000$4.99$49.90K12,768
Chad J. Kolean
Chief Financial Officer
Jul 2, 2025Buy+5,000$4.99$24.95K6,418
Jarrod Longcor
Chief Operating Officer
Jan 10, 2025Buy+30,000$0.28$8.40K83,141
Darrell Shane Lea
Chief Commercial Officer
Dec 8, 2023Award+39,599––39,599
James V. Caruso
President and CEO, Director
Dec 8, 2023Award+40,596––49,236
Chad J. Kolean
Chief Financial Officer
Dec 8, 2023Award+42,554––42,578
Andrei Shustov
Senior Vice President, Medical
Dec 8, 2023Award+47,856––55,038
Jarrod Longcor
Chief Operating Officer
Dec 8, 2023Award+42,927––53,141
Douglas J. Swirsky
Director
Sep 14, 2021Buy+25,000$1.04$26.00K25,000
Frederick W. Driscoll
Director
Sep 3, 2021Buy+19,417$1.04$20.19K19,417
James V. Caruso
President and CEO, Director
Mar 4, 2021Buy+5,100$1.70$8.67K86,401
Jarrod Longcor
Chief Business Officer
Dec 28, 2020Buy+29,630$1.35$40.00K102,148
James V. Caruso
President and CEO, Director
Dec 28, 2020Buy+37,037$1.35$50.00K81,301
Dov Elefant
Chief Financial Officer
Dec 28, 2020Buy+7,407$1.35$10.00K11,755
Dov Elefant
Chief Financial Officer
Jun 5, 2020Buy+4,348$1.15$5.00K4,348
Jarrod Longcor
Chief Business Officer
Jun 5, 2020Buy+65,218$1.15$75.00K72,518
James V. Caruso
President and CEO, Director
Jun 5, 2020Buy+21,740$1.15$25.00K44,264
Stephen A. Hill
Director
Jun 4, 2020Buy+18,000$1.08$19.44K18,000
James V. Caruso
President and CEO, Director
Feb 3, 2020Award+100,000$2.71$271.00K100,000
Dov Elefant
Chief Financial Officer
Feb 3, 2020Award+10,000$2.71$27.10K10,000
Jarrod Longcor
Chief Business Officer
Feb 3, 2020Award+40,000$2.71$108.40K40,000
Jarrod Longcor
Chief Business Officer
Feb 28, 2019Buy+100$2.00$2007,300
James V. Caruso
President and CEO, Director
Nov 30, 2018Buy+1,000$2.28$2.28K22,354
Stephen A. Hill
Director
Nov 29, 2018Sale−939$2.21$2.08K53
Stephen A. Hill
Director
Nov 29, 2018Sale−53$2.21$1170
Jarrod Longcor
Chief Business Officer
Aug 16, 2018Buy+500$2.71$1.36K7,200
Jarrod Longcor
Chief Business Officer
Mar 13, 2018Sale(10b5-1 plan)−13,000$1.18$15.34K67,000
James V. Caruso
President and CEO, Director
Mar 12, 2018Sale(10b5-1 plan)−34,000$1.20$40.80K213,548
John Neis
Director
Nov 14, 2017Sale−5,214$1.49$7.77K626,103
James V. Caruso
President and CEO, Director
Apr 18, 2017Award+200,000––247,548
Jarrod Longcor
Sr. VP of Corp Dev & Ops
Apr 18, 2017Award+80,000––80,000
Chad J. Kolean
VP, Chief Financial Officer
Apr 18, 2017Award+80,000––80,000
John E. Friend II
VP, Chief Medical Officer
Apr 17, 2017Award+100,000––100,000
John Neis
Director
Nov 29, 2016Buy+333,333$1.49$496.67K631,317
Richard Hertzberg
–
Oct 31, 2016Sale−21,000$2.03$42.63K280,000
Richard Hertzberg
–
Apr 21, 2016Buy+3,758$1.90$7.14K301,000
James V. Caruso
President and CEO, Director
Apr 20, 2016Buy+46,948$2.12$99.53K47,548
Paul L. Berns
Director
Apr 20, 2016Buy+117,371$2.12$248.83K117,371
John Neis
Director
Apr 20, 2016Buy+234,742$2.12$497.65K297,984
Stephen A. Hill
Director
Apr 20, 2016Buy+9,390$2.12$19.91K9,920
Richard Hertzberg
–
Apr 15, 2016Buy+234,742$2.12$497.65K297,242
AWM Investment Company, Inc.
10% owner
Dec 31, 2015Sale−35,253$0.70$24.68K0
AWM Investment Company, Inc.
10% owner
Dec 30, 2015Sale−64,747$0.69$44.68K35,253
AWM Investment Company, Inc.
10% owner
Dec 29, 2015Sale−82,847$0.69$57.16K100,000
Richard Hertzberg
10% owner
Dec 28, 2015Buy+75,000$0.72$54.00K75,000
AWM Investment Company, Inc.
10% owner
Dec 28, 2015Sale−150,975$0.69$104.17K182,847
Richard Hertzberg
10% owner
Dec 24, 2015Buy+50,000$0.79$39.50K50,000
AWM Investment Company, Inc.
10% owner
Dec 24, 2015Sale−216,991$0.76$164.91K333,822
Richard Hertzberg
10% owner
Dec 22, 2015Buy+5,000$0.91$4.55K5,000
AWM Investment Company, Inc.
10% owner
Dec 22, 2015Sale−7,938$0.90$7.14K550,813
AWM Investment Company, Inc.
10% owner
Dec 21, 2015Sale−20,621$0.92$18.97K558,751
AWM Investment Company, Inc.
10% owner
Dec 18, 2015Sale−7,000$0.90$6.30K579,372
AWM Investment Company, Inc.
10% owner
Dec 17, 2015Sale−18,240$0.88$16.05K586,372
Richard Hertzberg
10% owner
Dec 16, 2015Buy+19,592$0.91$17.83K19,592
AWM Investment Company, Inc.
10% owner
Dec 16, 2015Sale−52,985$0.86$45.57K604,612
AWM Investment Company, Inc.
10% owner
Dec 15, 2015Sale−44,965$0.82$36.87K657,597

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
2.34%
0M shares short
Days to cover
1.6
At 0M shares a day
Change since last report
-17.0%
From 0M shares
Short volume, 20 days
54.9%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cellectar Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,797 shares on Oct 13, 2026 over the last 90 days.

See a number that looks wrong?